Identification of integrated human herpesvirus 6 DNA in early pre-B cell acute lymphoblastic leukemia TO 
THE EDITOR
Human herpesvirus 6 (HHV-6) genome has been found in various types of malignant lymphomas including Hodgkin's disease and Burkitt's lymphoma. 1, 2 An association between HHV-6 infection and acute lymphoblastic leukemia (ALL) was first proposed in 1988 in a sero-epidemiological analysis showing a higher prevalence of HHV-6 antibody in patients with ALL than in healthy individuals. 3 Later, the presence of HHV-6 genome was demonstrated in childhood T cell ALL cells. 4 While these studies may emphasize an etiologic role of this lymphotropic virus in the pathogenesis of at least some cases of ALL, a subsequent study showed no significant difference between HHV-6 antibody titers in ALL patients and controls. 5 Thus, more evidence is required for understanding an interaction of HHV-6 with ALL.
In this report, we have studied a case of HHV-6-infected early pre-B cell ALL (also referred to as common ALL). The HHV-6 genome was abundantly present in a majority of the leukemic cells. We also demonstrated that the HHV-6 genome was integrated chromosomally in the ALL cells. To our knowledge, there has been no report of HHV-6 genome detected in B lineage ALL blasts.
The patient was an 83-year-old Japanese woman who was diagnosed as having L2 type ALL, according to the FrenchAmerican-British classification. The white blood cell count at diagnosis was 72.9 × 10 9 /l with 83% blasts. The leukemic cells displayed an early pre-B cell phenotype with a positivity for CD10 and CD19, but without expression of surface and cytoplasmic immunoglobulins. The cells carried t(9;22)(q24;q11) chromosomal abnormality resulting in generation of Philadelphia (Ph 1 ) chromosome. Serological anti-HHV-6 titers were 1:160 for IgG antibody and Ͻ1:10 for IgM antibody. Specimens were obtained from the diagnostic peripheral blood before therapy, and genomic DNA was extracted from the blast-enriched peripheral blood mononuclear cells (PBMCs) by using the phenol-chloroform extraction technique.
The presence of HHV-6 DNA sequences was first investigated by polymerase chain reaction (PCR). The DNA sample was clearly positive for HHV-6 DNA sequences. Representative results of the PCR analysis with the primers targeting the HHV-6 major capsid protein gene are shown in Figure 1a . The specificity of the PCR products was confirmed by Southern hybridization using an internal oligonucleotide probe. Another primer set specific for HHV-6 also gave a positive signal (Figure 1b) . In order to identify the HHV-6 variant in this patient by PCR, we used the primers covering sites of the immediate-early gene that flanked a region deleted in variant A, such that the resulting fragments were of different sizes. 6 Amplification with these primers resulted in generation of a 553-bp fragment, indicating that the infecting virus in this patient was HHV-6 variant B (Figure 1c) . The sequences of primers used in this study have been previously reported. 2 The presence of HHV-6 was confirmed on several separate occasions during the patient's clinical course. The search for Epstein-Barr virus sequences (BamW region) by PCR in the PBMCs of the patient was negative (data not shown). The cells were also examined for the presence of HHV-6 DNA by Southern blot hybridization using the BamHI fragment (6.9 kb) of HHV-6 as probe ( Figure 2 ). A single band was detected in the DNA sample from the patient.
We next employed HHV-6 DNA in situ hybridization (ISH) that is superior to PCR with respect to determination of the cells giving positive signals. PBMCs were collected when her leukocyte count showed 40.0 × 10 9 /l with 90% lymphoblasts. After being confirmed morphologically and immunophenotypically that the peripheral blood predominantly contained leukemic cells expressing CD10 antigen on their surface, the cells were subjected to ISH study ( Figure 3 ). ISH showed approximately 80% of the cells to be intensely stained. The positive signal was observed in the nuclei of the cells. The experiment was controlled by HHV-6-positive and -negative samples. The results indicated that the majority of the leukemic cells harbored the HHV-6 genome.
To examine the physical state of the persisting HHV-6 DNA, fluorescence in situ hybridization (FISH) on metaphase cells without any cultural step was performed. This technique allows the identification of integrated viral genome as well as episomal viral genome, since episomes should be associated with chromosomes randomly, whereas integrated copies should give rise to symmetrical hybridization signals on both chromatids at distinct chromosomal sites in the majority of the metaphases. Twenty-one metaphases were analyzed. Fluorescence signals were observed on chromosome 1 in 17 metaphase cells, most of which showed symmetrical doublet signals on both chromatids (Figure 4 ). Q-banding-like diamidino-2-phenylindole (DAPI) staining indicated that all signals on chromosome 1 appeared to be located at q44. The doublet signals on both chromatids of single homolog were observed only on chromosome 1 of the metaphase spreads, suggesting one integration site of HHV-6. The cells giving the positive hybridization signals possessed the Ph 1 chromosome. In parallel experiments, phytohemagglutinin (PHA)-stimulated PBMCs from a healthy donor did not show any signals after hybridization. The FISH analysis provides direct evidence to support the conclusion that HHV-6 DNA was present in the integrated form in the ALL blasts.
In search of a possible association of HHV-6 with ALL, we have encountered a case of early pre-B cell ALL infected with HHV-6. Since HHV-6 is a ubiquitous lymphotropic virus and probably, like other herpesviruses, remains latent for lifetime after primary infection, caution should be taken that the PCR positivity does not always imply the presence of HHV-6-infected leukemic cells. HHV-6 DNA could be detected in PBMCs of healthy individuals with varying frequencies when only highly sensitive PCR was used. HHV-6 DNA was detected in our patient not only by single step PCR using 
Figure 2
Detection of HHV-6 DNA by Southern blot analysis. Total cellular DNAs were digested with BamHI, subjected to electrophoresis through a 0.75% agarose gel, transferred onto a nylonmembrane filter, and hybridized with the BamHI fragment of HHV-6 DNA. The blot was developed by the enhanced chemiluminescence method. A hybridization band at 6.9 kb is seen in lanes 1 and 3. three sets of primers from diverse regions of the HHV-6 genome but also by Southern blot hybridization with the 6.9-kb fragment of HHV-6 as probe. The results suggested that an extraordinarily high copy number of HHV-6 sequences was present in this case. To discuss the association of HHV-6 with ALL, demonstration of this virus in pathologic blast cells is essential. We took advantage of ISH as it is useful for identification of cells harboring HHV-6 and confirmed the presence of HHV-6 genome in cytologically defined blast cells.
In previous surveys for HHV-6 DNA in ALL, one report described HHV-6 DNA in pathologic T lymphoblasts. 4 Barozzi et al 7 also demonstrated HHV-6 DNA sequences by sensitive PCR in some cases of B lineage ALL. However, possibly because of a very low copy number of viral sequences, their study did not identify cell types harboring HHV-6 and the PCR positivity may have reflected HHV-6-infected nonleukemic cells. To our knowledge, our observation is the first to demonstrate HHV-6 genome in B lymphoblasts. The existence of HHV-6 in leukemic cells might point to possible involvement of this virus in pathogenesis of at least some types of ALL.
In most herpesviruses previously reported, their DNA genomes usually persist extrachromosomally in latently infected cells. However, little is known about the status of HHV-6 in infected host cells. Making use of the FISH technique, we have found one chromosomal site which hybridized consistently with the HHV-6-specific probe in the Ph 1 chromosome-carrying leukemic cells. The symmetrical doublet signals on both chromatids of chromosome 1 in the majority of the metaphases suggested that the viral genome was integrated. Torelli et al 8 previously demonstrated HHV-6 integration on chromosome 17 in the PHA-stimulated PBMCs of patients with lym- phoma and multiple sclerosis. Our finding of HHV-6 integration on chromosome 1 in the leukemic cells, which is distinct from their report, may argue for random integration of HHV-6 rather than specific site integration. Additional studies on other HHV-6-infected cells, preferably on hematopoietic malignant cells, are required to determine whether integration is a constant feature of latent HHV-6 infection. Integration would be important for virus interaction with cellular genes, particularly those involved in cell growth regulation and tumorigenesis, because integration of viral genome may modify the expression of host cell proteins directly at the integration site, thereby leading to oncogenic transformation of the infected host cells. At present, we do not know whether integration of HHV-6 at the site of 1q44 exerts an oncogenic effect.
In summary, of particular importance in our study was the detection of HHV-6 genome within leukemic cells of B cell lineage. Our findings should stimulate further investigation concerning the association of HHV-6 with ALL. 
Fulminant hepatosplenic B cell lymphoma in a young patient with HCV-chronic hepatitis

TO THE EDITOR
A high prevalence of hepatitis C virus (HCV) infection has recently been described in patients with B cell non-Hodgkin lymphomas (NHL). [1] [2] [3] [4] On the other hand, we have not found any definitive report regarding the incidence rate of overt NHL in large cohorts of HCV-infected patients. 5 Specific clinical and histopathological characteristics in HCV-related lymphomas need to be defined. Significant differences have been reported in HCV genotypes. 2, 3 The histological spectrum of HCV-related NHL appears to be wide, lymphoplasmocytoid lymphoma, diffuse large B cell lymphoma and monocytoid B cell lymphoma emerging as the most common subtypes. [2] [3] [4] Extranodal primary involvement of the liver and/or spleen has been shown to be more frequent in HCV-infected patients 1, 3 compared with those uninfected. 3 So far, immunophenotypic and/or molecular characteristics have not been described in detail.
We report here the case of a 37-year-old Caucasian man, known to be infected with HCV for 3 years. The diagnosis of infection was made through routine testing of blood donation (serum anti-HCV antibodies) in April 1994. No previous blood transfusions and no history of intravenous drug abuse were reported. He confessed to have been a cocaine user in the past and alcohol consumption of about 30-50 g/day. HIV and HBV tests were negative. At that time he was asymptomatic and no organomegaly was present. The liver panel was normal. ANA, ASMA, anti-LKM, anti-thyroid and antimicrosomal antibodies were negative. A liver biopsy performed in May 1995 revealed chronic hepatitis (HAI = 4, stage 1 according to Knodell's scoring system) and interferon-alfa therapy was indicated. He remained asymptomatic until September 1997, when he was admitted to our hospital because of fatigue, anorexia, fever, profuse night sweating, polydipsia, weight loss (of 13 kg) and diffuse abdominal pain lasting 2 months. Physical examination showed cachexia, cutaneous and mucosal pallor, bilateral small painless axillary lymphadenopathy, abdominal collateral circulation and prominent and painful hepatosplenomegaly. Sjö gren's syndrome-related symptoms or clinical manifestations consistent with cryoglobulinemic activity were absent. Laboratory investigations showed hemoglobin 8.9 g/dl, white cell count 10.4 × 10 9 /l (81% neutrophils, 7% lymphocytes, 11% monocytes), platelet
